Comparing two schedules of rituximab maintenance in rituximab-responding patients with untreated, chemotherapy resistant or relapsed follicular lymphoma: a randomized phase III trial
Phase of Trial: Phase III
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 16 Jan 2018 Status changed from active, no longer recruiting to completed.
- 21 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
- 28 Dec 2015 Primary endpoint of event-free survival has not been met, according to results published in the Journal of Clinical Oncology.